Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma

Part of paid clinical trials in Dallas, Texas.

Sponsor
University of Texas Southwestern Medical Center
Study ID
NCT02781506
Phase
PHASE2
Status
Terminated

Conditions

  • Metastatic Clear Cell Renal Cell Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 100 Years
Healthy Volunteers
Not accepted

Interventions

  • Nivolumab — DRUG
    Nivolumab IV, administered per standard of care according to institutional guidelines at the discretion of the treating medical oncologist
  • SAbR — RADIATION
    SAbR (1-3 lesions)

Study Details

Nivolumab (brand name Opdivo): IV, administered per standard of care according to institutional guidelines at the discretion of the treating medical oncologist, until disease progression or unacceptable toxicity; SABR, dose variable, in 1-3 fractions.

Key Dates

Start date
Jun 20, 2016
Status verified
Jul 2022
Primary completion
May 24, 2021
Completion
May 24, 2021

Study Design

Enrollment
7 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Nivolumab and SABR
    Nivolumab alone: IV, administered per standard of care according to institutional guidelines at the discretion of the treating medical oncologist, until disease progression or unacceptable toxicity. SABR, dose variable, in 1-3 fractions.

Primary Outcome Measure

Response Rate (RR) [ Time Frame: 3 years ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of Texas Southwestern Medical CenterDallasTexas75390-

Find similar trials in Dallas, TX

By research site
University of Texas Southwestern Medical Center· Dallas, TX

Related Studies